PPIDT00245
Drug Information
| Name | Linaclotide |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB08890 |
| Type | small molecule |
| Indication | Linaclotide is indicated for the treatment of irritable bowel syndrome with constipation in adults. This indication is approved in the US, Canada, and Europe.[L47211, L47216, L47221] In the US and Canada, it is also indicated for the treatment of chronic idiopathic constipation in adults.[L47211, L47221] In the US, it is also indicated for the treatment of functional constipation in pediatric patients 6 to 17 years of age.[L47211] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Capsule | Oral |
145 mcg
|
| Capsule | Oral |
290 MICROGRAMMI
|
| Capsule | Oral |
290 mcg
|
| Capsule | Oral |
72 mcg
|
| Capsule | Oral |
0.145 mg
|
| Capsule, gelatin coated | Oral |
145 ug/1
|
| Capsule, gelatin coated | Oral |
290 ug/1
|
| Capsule, gelatin coated | Oral |
72 ug/1
|